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Abstract. The aim of this study was to investigate the pos-
sible inhibitory effect of ipriflavone on bone resorption
in rats. For this purpose, 10-week-old, intact and ovariec-
tomized (OVX) rats, prelabeled from birth with [3H]-
tetracycline, were used. Bone resorption was monitored by
measuring the urinary excretion of [3H]. The animals were
fed a purified diet devoid of naturally occurring flavonoids.
In the intact rats, the daily meal was given either as a single
portion or divided into four portions, a procedure known to
lead by itself to a decrease in bone resorption. Ipriflavone,
given 7 days after OVX at the dose of 400 mg/kg B.W. daily
mixed with the food, led within 2-3 days to a significant
decrease in bone resorption equivalent to that of 27.2 p g/kg
S.C. of 1713-estradiol. The inhibition was sustained for the
length of the experiment, up to 21 days. Ipriflavone given 7
days before OVX prevented the increase in bone resorption
induced by castration, the effect being dose-dependent be-
tween 50 and 400 mg/kg B.W. In contrast to 1713-estradiol,
a 5-week treatment with ipriflavone failed to prevent the
OVX-induced uterine atrophy. Significant inhibition of
bone resorption was also seen in intact animals, provided
they rapidly ingested the daily meal. Actually, the decrease
in bone resorption induced by portioning the daily food
masked the inhibitory effect of ipriflavone in intact animals.
In conclusion, ipriflavone can decrease bone resorption in
both intact and OVX animals given a purified diet as a
single daily meal. In the OVX model, ipriflavone mimics
the osteoprotective effect of estrogen. However, the lack of
a uterotropic effect suggests that the compound can dis-
criminate between bone and reproductive tissues.
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Ipriflavone is a synthetic derivative of a natural isoflavone.
First clinical trials indicate that the compound exerts a ben-
eficial effect in osteopenic diseases [1-3]. It is not clear yet
whether ipriflavone acts primarily by inhibiting bone re-
sorption or by stimulating bone formation. Inhibition of
osteoclast recruitment in both in vitro [4, 5] and in vivo [6],
and induction of markers of the osteoblast phenotype in
vitro [7, 8] have been demonstrated. However, in the rat
model of osteopenia following ovariectomy [9], ipriflavone
did not reduce bone resorption when administered alone,
but it did enhance the therapeutic effects of estrogen. Con-
founding factors may explain the lack of the protective ef-
fect of ipriflavone per se on bone loss due to estrogen with-
drawal in animals. Therefore, we investigated in vivo the
modalities by which an intrinsic inhibitory activity of ipri-
flavone on bone resorption can be disclosed.
For measuring bone resorption, we used a technique
based on long-term prelabeling with [3H]-tetracycline and
the subsequent determination of urinary excretion of the
tracer (Fig. 1). This technique allows monitoring of bone
resorption, daily or at shorter intervals, over extended peri-
ods of time [10].
According to the components used, rat chow may con-
tain large amounts of naturally occurring flavonoids. In or-
der to exclude substances that might interfere with the effect
of ipriflavone, and to mimic a typical human "western
diet" with large proportions of refined components, we
have used a "purified" diet that contains casein as the
protein source and starch as the carbohydrate source. In rats
fed this diet, ipriflavone significantly reduced bone resorp-
tion induced by ovariectomy.
Surprisingly, ipriflavone given to intact rats failed to
show any appreciable effect on bone resorption. However,
careful recording of the feeding habit revealed that intact
animals given ipriflavone mixed with the food ingested their
meals at a slower rate than control rats.
Bone resorption in the rat displays a diurnal rhythm that
is blunted by food fractionation [11]. Therefore, we have
compared the effect of ipriflavone on intact animals ingest-
ing the daily food either as a single meal or fractionated into
four portions. We found that ipriflavone was inhibiting bone
resorption only in rats that were rapidly ingesting their daily
food as a single meal.
Material and Methods
Animals
At the age of 7 weeks, Wistar rats from our own breeding colony
were housed in individual metabolic cages. Until the experiments,
all animals had free access to tap water and were fed a standard
laboratory chow ad libitum (Kliba 331; Klingentalmuhle, Kaiser-
augst, Switzerland), containing 1.0 g Ca, 0.7 g P and 80 IU vita-
min-D3/100 g dry weight. During the experiments, some groups
continued to receive lab chow, 14 g dry weight per day. The other
groups were switched to the purified diet (see introduction), 14.7
g dry weight per day, containing 1.1 g Ca and 1.2 g P/100 g dry
weight.
[3H]-tetracycline Labeling
Beginning at the age of 2-3 days, the rats were injected twice a
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Fig. 1. Schematic representation of the experimental protocol
used for monitoring bone resorption in rats with the urinary ex-
cretion of [3H]-tetracycline.
10 µCi/ml of [3H]-tetracycline ([3H]-TC) (New England Nuclear,
Boston, MA) dissolved in 0.15 M NaCl, as described previously
[10].
Feeding Schedule
Wet food (26 g) corresponding to 14.7 g of dry matter, was pro-
vided at 11 A.M. In the experiment with food fractionation the rats
received 24 g of wet food, corresponding to 13.5 g of dry matter,
provided either as a single meal at 11 A.M., or in four portions of
6 g each, every 6 hours. Before the experiment started, all animals
were trained to ingest the entire amount of food within 2 hours. In
all cases the animals had free access to tap water.
Urine Collection
After a 7-10-day adaptation, the urine was collected every 24
hours and the [3H] content was determined by liquid scintillation
spectrometry, as previously described [10]. After an initial 5-7 day
monitoring of the baseline urinary [ 3H]-excretion, the animals
were randomly allocated to treatment groups.
Ovariectomy
For some experiments, the rats, aged 9-9.5 weeks, were either
bilaterally ovariectomized (OVX) or sham-operated (SHAM) un-
der ether anesthesia. In the SHAM rats, the ovaries were bilaterally
exposed and handled, but not removed. To verify complete re-
moval of the ovaries, at the end of the experimental period the
uterus was excised and the weight was determined.
Treatment
Ipriflavone was carefully mixed with the food, as dry substance, at
daily doses of 400, 150, and 50 mg/kg B.W. When the experimen-
tal protocol included OVX, the compound was administered either
7 days before or 7 days after the surgical intervention.
17(3-estradiol (Sigma, St. Louis, MO), dissolved in corn oil,
was administered subcutaneously to OVX rats, beginning either on
the day of surgery or 7 days after, at the daily dose of 27.2 p g/kg
B.W. immediately before the 11 A.M. meal.
Treatment with both ipriflavone and 17[3-estradiol was main-
tained until the end of each experiment.
Statistics
Statistical differences between experimental groups were assessed
by one-way analysis of variance, followed by the posthoc New-
man-Keuls multiple comparison test. A P value of less than 0.05
was considered significant.
Results
Effect of Ipriflavone on Bone Resorption in OVX Rats
First we investigated whether ipriflavone could prevent or
arrest the OVX-induced bone resorption. Within 1 week
from castration bone resorption in OVX rats significantly
increased, attaining an average of 40% increase in bone
resorption as compared with SHAM animals. 17(3-estradiol,
administered daily starting on the day of OVX, maintained
bone resorption at the same level of SHAM (P < 0.01 versus
OVX). Ipriflavone, administered to OVX rats starting 7
days before or after castration at the daily dose of 400
mg/kg B.W., was equally effective as 1713-estradiol in re-
ducing OVX-induced bone resorption to the values of
SHAM animals (P < 0.001 or P < 0.01 versus OVX when
given from day —7 or day +7, respectively). In addition,
there was a slight inhibition of basal bone resorption already
during the period of administration prior to castration.
Next, we investigated whether the inhibitory effect of
ipriflavone on OVX-induced bone resorption was dose de-
pendent. The various daily doses of ipriflavone were ad-
ministered and mixed with food beginning 7 days before
OVX to rats fed with purified diet. Doses of 50 and 150
mg/kg B.W. reduced bone resorption significantly (P < 0.01
and P < 0.05 versus OVX, respectively), both attaining an
average of 50% of the inhibitory effect exerted either by
1713-estradiol or ipriflavone, 400 mg/kg B.W., given in the
same experiment. The uterine weight of OVX rats was not
significantly affected by ipriflavone at any of the doses
administered. In contrast, the uterine weight of the OVX
animals that received 1713-estradiol did not differ signifi-
cantly from that of the SHAM animals.
Effect of Ipriflavone on Bone Resorption in Intact Rats
When we investigated the effect of ipriflavone in intact rats
fed with the purified diet, the compound was unable to
significantly influence basal bone resorption. However,
careful recording of the feeding habit revealed that intact
animals given ipriflavone mixed with the food ingested the
meal at a slower rate than control rats. Fractionation of daily
food intake by itself decreases bone resorption [111  and this
mechanism may have masked the inhibitory effect of ipri-
flavone on bone resorption in intact animals eating slowly.
In contrast, OVX animals, known to be prone to increased
appetite, did not present relevant modifications of their
feeding habit when treated with ipriflavone. This may ex-
plain the discrepancy in effect of ipriflavone between intact
and OVX rats.
A subsequent experiment showed that indeed iprifla-
vone, at the daily dose of 400 mg/kg B.W., significantly
inhibited (P < 0.01) basal bone resorption in intact rats that
were previously trained to rapidly ingest the daily food as a
single portion. In contrast, ipriflavone, at the same dose,
failed to reduce bone resorption when administered to intact
rats that consumed the daily food fractionated into four
portions.
Discussion
In this study we demonstrate that ipriflavone per se inhibits
bone resorption, both in intact and OVX rats that are fed a
purified diet that is likely to be devoid of flavonoids and
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other compounds that mimic estrogen effects on some target
tissues. In the OVX rats the magnitude of the effect of a
daily dose of 400 mg/kg B.W. of ipriflavone is equivalent to
that of 170-estradiol at the daily dose of 27.2 pg/kg B.W.
Furthermore, we show that the effect of ipriflavone is no
longer evident when the daily food is fractionated, a proce-
dure that by itself decreases bone resorption [11].
It has previously been reported that ipriflavone, when
administered alone, could not prevent bone loss in the OVX
rat [9]. The fact cannot be excluded that in that study, natu-
ral flavonoids contained in the "commercial diet" used or
slow food consumption may have masked the effect of ipri-
flavone.
It is not known whether similar confounding factors may
be relevant in the human species. Ipriflavone per se has
been shown to exert beneficial effects on the osteopenia
induced in women by either iatrogenic [2] or physiological
estrogen deficiency [1, 3]. Nevertheless, it is well docu-
mented that dietary flavonoids alter the hormonal status of
premenopausal women [12]. Accordingly, the possibility
that the diet composition and/or meal frequency may play a
role in the clinical evaluation of the therapeutic effect of
ipriflavone should be taken into account.
Recently, it has been elucidated in vitro that neither ipri-
flavone nor the majority of its metabolites interact directly
with classical type I estrogen receptors [13]. However, ipri-
flavone and its biologically most active metabolite III bind
to nuclear receptors that are likely to be part of the steroid
receptor superfamily [13]. Consistent with these findings in
vitro, it has been reported previously that ipriflavone by
itself is devoid of any estrogenic effect in both OVX ani-
mals [9, 14] and in postmenopausal women [15]. Our pres-
ent investigation confirms that the compound does not exert
uterotropic effects in OVX animals.
The evidence stated above, indicating that ipriflavone
counteracts bone loss due to estrogen deficiency while not
exerting an uterotropic effect, suggests that this compound
may behave as a selective estrogen receptor modulator
(SERM). Other compounds, such as raloxifene [16] and
droloxifene [17], with the characteristics of the SERMs,
have been proposed as pharmacological inhibitors of post-
menopausal bone loss. However, in contrast to ipriflavone,
these two compounds have been shown to interact with
classical estrogen receptors [18, 19] and exert a slight but
significant uterotropic effect in OVX rats [16, 17]. Thus,
ipriflavone may represent a class of compounds that mimic
the protective effect of estrogen on bone tissue by a mecha-
nism that seems to involve a transduction pathway different
from that of estrogen. Interestingly, a diet rich in flavonoids
has been shown to reduce serum cholesterol [12]. Further
investigations are warranted in order to verify whether ipri-
flavone exerts a protective effect also against the increased
risk of developing ischemic heart disease characteristic of
postmenopausal women.
While clearly demonstrating that ipriflavone can inhibit
bone resorption in the rat, the present study also suggests
that confounding factors such as diet formulation and/or
feeding habit should be taken into consideration when in-
vestigating the protective effect against bone loss of new
compounds in experimental animals.
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